The MonashIVFchief executive, Michael Knaap, has resigned in the wake of the reproductive healthcare company’s second embryo transplant bungle.
In a statement to the ASX, Monash IVF said the board had accepted Knaap’s resignation as CEO and managing director.
This week, Monash IVF admitted toa second bungled embryo implant. In an earlier error in April, Monash IVF revealed a woman had given birth to the child of an unrelated woman afteran incorrect embryo transplantin Queensland.
Monash IVF said in the statement on Thursday that it “acknowledges and respects [Knaap’s] decision”.
“Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and we thank him for his years of dedicated service,” the statement said.
Malik Jainudeen, Monash IVF’s chief financial officer and company secretary, will serve as acting chief executive.
Experts are now calling for national regulation of the sector, something that the health minister, Mark Butler, said would be discussed on Friday when health ministers meet in Melbourne.
Currently, IVF is regulated by state and territory laws, but a more consistent, federal approach is being urged.
Clinics must be licensed by the Reproductive Technology Accreditation Committee (RTAC), a subcommittee of the Fertility Society of Australia and New Zealand (FSANZ). That’s the unit that carries out audits, including on some assisted reproductive technology (ART) clinics internationally.
Sign up for Guardian Australia’s breaking news email
Clinics must also follow ethical guidelines from the NationalHealthand Medical Research Council.
FSANZ said in a statement about the latest Monash IVF incident that Australia’s fertility care system was “among the safest, most transparent, and tightly regulated in the world”.
Dr Petra Wale, the FSANZ president, said errors were “exceedingly rare” although “deeply difficult for those affected”.
FSANZ has called for a nationally consistent framework for ART, and an independent statutory authority to “strengthen oversight and trust”. It said that while the clinical standards in IVF clinics are nationally consistent, each state and territory has its own legislation.
Transitioning the RTAC to an independent statutory authority would strengthen the accreditation scheme with “the regulatory clarity and operational flexibility needed to uphold rigorous standards and respond swiftly to emerging risks”, it said, while a national approach to ART would “strengthen transparency, streamline governance, and enhance patient care across the country”.
The latest audit of Australian ART facilities found 172 non-conformance reports (NCRs), but only one was “major”. Other countries audited, including New Zealand, had higher rates of NCRs.
Sign up toAfternoon Update
Our Australian afternoon update breaks down the key stories of the day, telling you what’s happening and why it matters
after newsletter promotion
Prof Jeremy Thompson, a fertility researcher at the University of Adelaide and the co-founder and chief scientific officer at the IVF technology company Fertilis, said there was a global shortage of well-trained and experienced embryologists.
This means “levels of training and experience can vary”, Thompson said, in a stressful job where “skill and time management are critical for the best outcome”.
But he said that “Australia’s reputation as a leader in embryology training and technique auditing is beyond question”.
The University of New South Wales associate professor Kuldip Sidhu, co-founder and director of CK Cell Technologies, said more rigorous compliance was needed in the industry.
Embryologists are not currently registered under a national scheme, and doing this would “help in adding another layer of responsibility to check such mishappenings in the IVF industry”, he said.
Dr Evie Kendal, a senior lecturer in health promotion at Swinburne University of Technology, said that with more human intervention in reproduction there was an increased potential for human error.
“Previous safeguards are clearly not up to the challenge of protecting clients against such incidents, and urgent ethical and policy guidance is needed to prevent such mistakes from occurring again,” she said.
On Tuesday, Monash IVF told the ASX it would extend the review into the Queensland incident and start a new investigation into the Victorian one.
Victoria’s health minister, Mary-Anne Thomas, confirmed the Victorian health regulator was also investigating. She said Monash IVF’s “clinical governance standards are not where they should be”.
Monash IVF said on Tuesday that as well as the investigations it would put extra verification processes and patient confirmation safeguards in place “over and above normal practice and electronic witness systems, to ensure patients and clinicians have every confidence in its processes”.